

CTI BIOPHARMA CORP  
Form DEFA14A  
March 28, 2017

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934

Filed by the Registrant:  Filed by a Party other than the Registrant:

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-12

CTI BioPharma Corp.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of filing fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

---

(2) Aggregate number of securities to which transaction applies:

---

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

---

(4) Proposed maximum aggregate value of transaction:

---

(5) Total fee paid:

---

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

---

(2) Form, Schedule or Registration Statement No.:

---

(3) Filing Party:

---

(4) Date Filed:

---



\*\*\* Exercise Your Right to Vote \*\*\*

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on May 16, 2017.

CTI BIOPHARMA CORP.

Meeting Information

Meeting Type: Annual Meeting

For holders as of March 15, 2017

Date: May 16, 2017 Time: 10:00AM Pacific Time

Location: Company's Principal Executive Offices  
3101 Western Avenue, Suite 600  
Seattle, WA 98121, U.S.A.

CTI BIOPHARMA CORP.  
3101 WESTERN AVENUE, SUITE 600  
SEATTLE, WA 98121

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at [www.proxyvote.com](http://www.proxyvote.com) or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

1. NOTICE AND PROXY STATEMENT 2. 2016 ANNUAL REPORT

How to View Online:

Have the information that is printed in the box marked by the arrow

è XXXX XXXX XXXX (located on the

following page) and visit: [www.proxyvote.com](http://www.proxyvote.com).

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Shareholders may also request paper or e-mail copies of the proxy materials for all future meetings.

Please choose one of the following methods to make your request:

- 1) BY INTERNET: [www.proxyvote.com](http://www.proxyvote.com)
- 2) TELEPHONE: 1-800-579-1639
- 3) BY E-MAIL\*: [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com)

\* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow è XXXX XXXX XXXX (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 2, 2017 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many shareholder

meetings have attendance

requirements including, but not

limited to, the possession of an

attendance ticket issued by the entity

holding the meeting. Please check the

meeting materials for any special

requirements for meeting attendance.

At the meeting, you will need to

request a ballot to vote these shares.

Directions to the meeting are available

at

[www.ctibiopharma.com/shareholders](http://www.ctibiopharma.com/shareholders).

Vote By Internet: To vote now by

Internet, go to [www.proxyvote.com](http://www.proxyvote.com).

Have the information that is printed in

the box marked by the arrow è XXXX

XXXX XXXX (located on the

following page) available and follow

the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

---

Voting  
Items  
The Board of  
Directors  
recommends  
you vote  
FOR ALL the  
following:

To elect directors to  
the Company's

1. Board of  
Directors to serve  
one-year terms.

Nominees:

01)

Adam

05)

R. Matthew

Craig

D. Perry

M.D.,

Ph.D.

02)

Jack

Richard

L. Singer,

M.D.

07)

03)

Frederick

Michael

W.

A. Telling,

Metzger

Ph.D.

04)

08) Reed

Philip

Tuckson,

N. Medman,

Ph.D. C.P.

The Board of Directors  
recommends you vote  
ONE YEAR on Proposal  
6 and FOR the other  
following proposals:

2. To approve an  
amendment to the  
Company's amended  
and restated articles

of incorporation to increase the total number of authorized shares from 41,533,333 to 81,533,333 and to increase the total number of authorized shares of common stock from 41,500,000 to 81,500,000;

3. To approve the Company's 2017 Equity Incentive Plan;

To ratify the selection of Marcum LLP as the

4. Company's independent auditor for the year ending December 31, 2017;

5. To approve, by non-binding advisory vote, the compensation of the Company's named executive officers;

6. Provide an advisory vote to determine whether an advisory vote on executive compensation should occur every one, two or three years; and

7. To approve the adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the

Annual Meeting to  
adopt any of  
Proposals 1 through  
6.

NOTE: In their  
discretion, the proxies  
are authorized to vote  
upon such other business  
as may properly come  
before the Annual  
Meeting or any  
adjournments and  
postponements thereof.

---



